Preoperative [(18)F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권현우 | - |
dc.contributor.author | Kwon, Hyun Woo | - |
dc.date.accessioned | 2021-09-03T09:52:53Z | - |
dc.date.available | 2021-09-03T09:52:53Z | - |
dc.date.created | 2021-06-21 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84565 | - |
dc.description.abstract | Objective: To determine whether [(18)F]FDG uptake on PET/CT imaging before surgical staging has prognostic significance in patients with epithelial ovarian cancer (EOC). Methods: Patients with EOC were imaged with integrated PET/CT before surgical staging. Hypermetabolic lesions were measured as the standardized uptake value (SUV) in primary and metastatic tumors. SUV distribution was divided into two regions at the level of umbilicus, and the impact of the ratio between above and below umbilicus (SUV(location) ratio) on progression-free survival (PFS) was examined using Cox proportional hazards regression. Results: Between January 2004 and December 2009, 55 patients with EOC underwent preoperative PET/CT. The median duration of PFS was 11 months (range, 3 to 43 months), and twenty (36.4%) patients experienced recurrence. In univariate analysis, high SUV(location), on ratio (p=0.002; hazard ratio [HR], 1.974; 95% confidence interval [Cl], 1.286 to 3.031) was significantly associated with recurrence. Malignant mixed mullerian tumor compared with endometrioid histology was also shown to have significance. In multivariate analysis, high SUV(location) ratio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447) and histology (serous, mucinous, and malignant mixed mullerian tumor compared with | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY | - |
dc.title | Preoperative [(18)F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 권현우 | - |
dc.contributor.affiliatedAuthor | Kwon, Hyun Woo | - |
dc.identifier.doi | 10.3802/jgo.2012.23.1.28 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, v.23, pp.28 - 34 | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.title | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.volume | 23 | - |
dc.citation.startPage | 28 | - |
dc.citation.endPage | 34 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Distribution | - |
dc.subject.keywordAuthor | Epithelial ovarian cancer | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordAuthor | Standardized uptake value | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.